Clinical Pharmacokinetics and Pharmacodynamics of Dasatinib
The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
Dasatinib is an oral, once-daily tyrosine kinase inhibitor used in the treatment of chronic myeloid leukaemia and Philadelphia chromosome-positive acute lymphoblastic leukaemia. Dasatinib is rapidly absorbed, with the time for maximal serum concentration varying between 0.25 and 1.5 h. Oral absorption is not affected by food. The absolute bioavailability of dasatinib in humans is unknown due to the lack of an intravenous formulation preventing calculation of the reference exposure. Dasatinib is eliminated through cytochrome P450 (CYP) 3A4-mediated metabolism, with a terminal half-life of 3-4 h. Based on total radioactivity, only 20% of the oral dose (100 mg) is recovered unchanged in faeces (19%, including potential non-absorption) and urine (1%) after 168 h. Dasatinib pharmacokinetics are not influenced by age (children, and adults up to 86 years of age), race and renal insufficiency. Dasatinib absorption is decreased by pH-modifying agents (antacids, H 2-receptor blockers, proton pump inhibitors), and dasatinib is also subject to drug interactions with CYP3A4 inducers or inhibitors.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“both D and Q have very short half-lives (3–4 h27 and 3.5 h28, respectively), so once-monthly administration of these drugs would be very unlikely to have direct effects on bone turnover weeks following administration.”
From Effects of intermittent senolytic therapy on bone metabolism in postmenopausal women: a phase 2 randomized controlled trial (2024) · cites this paper as [27]
Citations
Cites
Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor
Shah, N. P., Tran, C., Lee, F. Y., Chen, P., Norris, D., & Sawyers, C. L. (2004) · Science · doi:10.1126/science.1099480 · Cited by 1,796
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias
Talpaz, M., Shah, N. P., Kantarjian, H., Donato, N., Nicoll, J., Paquette, R., Cortes, J., O'Brien, S., Nicaise, C., Bleickardt, E., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055229 · Cited by 1,760 · cited 2×
“Dasatinib was first approved as an alternative to previous therapies, including imatinib (the first marketed kinase inhibitor against bcr-abl, introduced in 2001) in case of intolerance or resistance [4].”
BackgroundMethodCortes, J. E., Saglio, G., Kantarjian, H. M., Baccarani, M., Mayer, J., Boqué, C., Shah, N. P., Chuah, C., Casanova, L., Bradley-Garelik, B., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.8899 · Cited by 947
Shah, N. P., Kantarjian, H. M., Kim, D.-W., Réa, D., Dorlhiac-Llacer, P. E., Milone, J. H., Vela-Ojeda, J., Silver, R. T., Khoury, H. J., Charbonnier, A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.9260 · Cited by 489
Porkka, K., Koskenvesa, P., Lundán, T., Rimpiläinen, J., Mustjoki, S., Smykla, R., Wild, R., Luo, R., Arnan, M., Brethon, B., et al. (2008) · Blood · doi:10.1182/blood-2008-02-140665 · Cited by 445
Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring
Jabbour, E., & Kantarjian, H. (2018) · American Journal of Hematology · doi:10.1002/ajh.25011 · Cited by 413
Slayton, W. B., Schultz, K. R., Kairalla, J. A., Devidas, M., Mi, X., Pulsipher, M. A., Chang, B. H., Mullighan, C., Iacobucci, I., Silverman, L. B., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.7228 · Cited by 245
Shen, S., Chen, X., Cai, J., Yu, J., Gao, J., Hu, S., Zhai, X., Liang, C., Ju, X., Jiang, H., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2019.5868 · Cited by 239
Metabolism and disposition of dasatinib after oral administration to humans
Christopher, L. J., Cui, D., Wu, C., Luo, R., Manning, J. A., Bonacorsi, S. J., Lago, M., Allentoff, A., Lee, F. Y. F., McCann, B., et al. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.018267 · Cited by 202
P-glycoprotein and Breast Cancer Resistance Protein Influence Brain Distribution of Dasatinib
Chen, Y., Agarwal, S., Shaik, N. M., Chen, C., Yang, Z., & Elmquist, W. F. (2009) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.154781 · Cited by 194
Cited by
Senolytic therapy ameliorates renal fibrosis postacute kidney injury by alleviating renal senescence
Li, C., Shen, Y., Huang, L., Liu, C., & Wang, J. (2021) · The FASEB Journal · doi:10.1096/fj.202001855rr · Cited by 119
Farr, J. N., Atkinson, E. J., Achenbach, S. J., Volkman, T. L., Tweed, A. J., Vos, S. J., Ruan, M., Sfeir, J., Drake, M. T., Saul, D., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03096-2 · Cited by 127
Millar, C. L., Iloputaife, I., Baldyga, K., Norling, A. M., Boulougoura, A., Vichos, T., Tchkonia, T., Deisinger, A., Pirtskhalava, T., Kirkland, J. L., et al. (2025) · EBioMedicine · doi:10.1016/j.ebiom.2025.105612 · Cited by 88
Lipton, J. H., Brümmendorf, T. H., Gambacorti-Passerini, C. B., García‐Gutiérrez, V., Deininger, M. W., & Cortes, J. E. (2022) · Blood Reviews · doi:10.1016/j.blre.2022.100968 · Cited by 74
Zhu, X., Zhang, C., Liu, L., Xu, L. N., & Yao, L. (2024) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2024.5350 · Cited by 64
Metadata
- Authors
- Levêque, D., Becker, G., Bilger, K., & Natarajan-Amé, S.
- Affiliations
- Hôpital d'Hautepierre (FR)
- Corresponding author
- Levêque, Dominique
- Venue
- Clinical Pharmacokinetics
- Published
- 2020-02-29
- Volume
- 59
- Issue
- 7
- Pages
- 849-856
- ISSN
- 0312-5963 (ISSN-L)
- 1179-1926
- OpenAlex
- W3007045996
- Cited by
- 90
- References
- 41
- Citations by year
- 2026: 14 · 2025: 14 · 2024: 20 · 2023: 16 · 2022: 11 · 2021: 14 · 2020: 1
- FWCI
- 1.65
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Clinical Pharmacokinetics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Chronic Myeloid Leukemia Treatments
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Keywords
- dasatinib, tyrosine kinase inhibitors, chronic myeloid leukemia, Philadelphia chromosome-positive acute lymphoblastic leukemia, pharmacokinetics, pharmacodynamics, CYP3A4 metabolism, bioavailability, drug interactions, food effect, renal failure
- MeSH terms
- Dasatinib, Antineoplastic Agents, Biological Availability, Drug Interactions, Humans, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Protein Kinase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical Pharmacokinetics and Pharmacodynamics of Dasatinib. https://app.cochat.ai/papers/10.1007/s40262-020-00872-4
- The paper
- Levêque, D., Becker, G., Bilger, K., & Natarajan-Amé, S. (2020). Clinical Pharmacokinetics and Pharmacodynamics of Dasatinib. Clinical Pharmacokinetics. https://doi.org/10.1007/s40262-020-00872-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.